Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers

Nitric Oxide - Biology and Chemistry

Volumn 9, Issue 4, 2003, Pages 211-216

  Barnabé, Norman ^a   Marusak, Rosemary A ^b   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b KENYON COLLEGE   (United States)

Author keywords

Antioxidant; Cardiotoxicity; Doxorubicin; EPR; Iron; L NAME; Myocyte; Nitric oxide

Indexed keywords

ARGININE DERIVATIVE; ASCORBIC ACID; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; N(G) METHYL DEXTRO ARGININE; N(G) METHYLARGININE; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEMIQUINONE;

ANIMAL CELL; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON SPIN RESONANCE; ENZYME RELEASE; HEART MUSCLE CELL; HEART MUSCLE INJURY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPIN TRAPPING;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; ARGININE; ASCORBIC ACID; BENZOQUINONES; DOXORUBICIN; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; L-LACTATE DEHYDROGENASE; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 1442299822     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2003.12.001     Document Type: Article

References (41)

1. Gianni L., Corden B.J., Myers C.E. The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev. Biochem. Toxicol. 5:1983;1-82.
2. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19:1992;670-686.
3. Gianni L., Zweier J.L., Levy A., Myers C.E. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J. Biol. Chem. 260:1985;6820-6826.
4. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem. 207:2000;77-86.
5. Bachur N.R., Gordon S.L., Gee M.V., Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA. 76:1979;954-957.
6. Barnabé N., Zastre J., Venkataram S., Hasinoff B.B. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33:2002;266-275.
7. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochim. Biophys. Acta. 884:1986;326-336.
8. Malisza K.L., Hasinoff B.B. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch. Biochem. Biophys. 321:1995;51-60.
9. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A. Jr., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 36:1997;11293-11297.
10. Garner A.P., Paine M.J., Rodriguez-Crespo I., Chinje E.C., Ortiz D.M.P., Stratford I.J., Tew D.G., Wolf C.R. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59:1999;1929-1934.
11. Vasquez-Vivar J., Hogg N., Martasek P., Karoui H., Tordo P., Pritchard K.A. Jr., Kalyanaraman B. Effect of redox-active drugs on superoxide generation from nitric oxide synthases: biological and toxicological implications. Free Radic. Res. 31:1999;607-617.
12. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 276:2001;47266-47276.
13. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 234-235:2002;119-124.
14. Hasinoff B.B., Patel D., Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic. Biol. Med. 35:2003;1469-1479.
15. Hasinoff B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2:2002;111-118.
16. Hershko C., Link G., Tzahor M., Kaltwasser J.P., Athias P., Grynberg A., Pinson A. Anthracycline cytotoxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. 122:1993;245-251.
17. Ek B., Hallberg C., Sjogren K.-G., Hjalmarson A. Reoxygenation-induced cell damage of isolated neonatal rat ventricular myocytes can be reduced by chain-breaking antioxidants. Free Radic. Biol. Med. 16:1994;117-121.
18. Griffith O.W., Kilbourn R.G. Nitric oxide synthase inhibitors: amino acids. Methods Enzymol. 268:1996;375-392.
19. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 273:1998;25804-25808.
20. G-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry. 32:1993;9677-9685.
21. Keefer L.K., Nims R.W., Davies K.M., Wink D.A. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 268:1996;281-293.
22. Schluter K.D., Jakob G., Ruiz-Meana M., Garcia-Dorado D., Piper H.M. Protection of reoxygenated cardiomyocytes against osmotic fragility by nitric oxide donors. Am. J. Physiol. 271:1996;H428-H434.
23. Monastyrskaya E., Folarin N., Malyshev I., Green C., Andreeva L. Application of the nitric oxide donor SNAP to cardiomyocytes in culture provides protection against oxidative stress. Nitric Oxide. 7:2002;127-131.
24. Moroz L.L., Norby S.W., Cruz L., Sweedler J.V., Gillette R., Clarkson R.B. Non-enzymatic production of nitric oxide (NO) from NO synthase inhibitors. Biochem. Biophys. Res. Comm. 253:1998;571-576.
25. Kotake Y. Continuous and quantitative monitoring of rate of cellular nitric oxide generation. Methods Enzymol. 268:1996;222-229.
26. 3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin Cancer Res. 50:1990;2307-2310.
27. Hasinoff B.B. Chemistry of dexrazoxane and analogues. Semin. Oncol. 25(Suppl. 10):1998;3-9.
28. Meyers C.E. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 25(Suppl. 10):1998;10-14.
29. Hochster H., Liebes L., Wadler S., Oratz R., Wernz J.C., Meyers M., Green M., Blum R.H., Speyer J.L. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84:1992;1725-1730.
30. Matsuda H., Kimura S., Iyanagi T. One-electron reduction of quinones by the neuronal nitric-oxide synthase reductase domain. Biochim. Biophys. Acta. 1459:2000;106-116.
31. Jiang H.B., Ichikawa M., Furukawa A., Tomita S., Ichikawa Y. Reductive activation of mitomycin C by neuronal nitric oxide synthase. Biochem. Pharmacol. 60:2000;571-579.
32. Jiang H.B., Ichikawa Y. Neuronal nitric oxide synthase catalyzes the reduction of 7-ethoxyresorufin. Life Sci. 65:1999;1257-1264.
33. Miller R.T., Martasek P., Roman L.J., Nishimura J.S., Masters B.S. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry. 36:1997;15277-15284.
34. Kumagai Y., Nakajima H., Midorikawa K., Homma-Takeda S., Shimojo N. Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: nitric oxide synthase as a quinone reductase. Chem. Res. Toxicol. 11:1998;608-613.
35. Bredt D.S., Hwang P.M., Glatt C.E., Lowenstein C., Reed R.R., Snyder S.H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 351:1991;714-718.
36. Konorev E.A., Kennedy M.C., Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch. Biochem. Biophys. 368:1999;421-428.
37. Greenberg S.S., Xie J., Spitzer J.J., Wang J.F., Lancaster J., Grisham M.B., Powers D.R., Giles T.D. Nitro containing L-arginine analogs interfere with assays for nitrate and nitrite. Life Sci. 57:1995;1949-1961.
38. Nagase S., Takemura K., Ueda A., Hirayama A., Aoyagi K., Kondoh M., Koyama A. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine. Biochem. Biophys. Res. Commun. 233:1997;150-153.
39. Fernandez-Tome P., Lizasoain I., Leza J.C., Lorenzo P., Moro M.A. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones. Neuropharmacology. 38:1999;1307-1315.
40. Kelley E.E., Wagner B.A., Buettner G.R., Burns C.P. Nitric oxide inhibits iron-induced lipid peroxidation in HL-60 cells. Arch. Biochem. Biophys. 370:1999;97-104.
41. Nonami Y., Rao V., Shiono N., Ogoshi S. Quenching the effects of L-arginine on free radical injury in cultured cardiomyocytes. Surg. Today. 28:1998;379-384.